The last weekend of September, oncologists, thoracic surgeons and more gathered in Canada for the World Conference on Lung Cancer. The meeting reviewed new research and potentially practice-changing abstracts. If you missed the conference, check out some highlights from twitter.
People shared snippets from their favorite talks or what they were most stunned by.
Another Important Debate: Large Cell Neuroendocrine Carcinoma should be Treated like NSCLC or SCLC? More Translational Research Needed! #iaslc #WCLC18 #lungpath #onco @hospitalclinic @NReguart pic.twitter.com/lDT1u1HidL— Cristina Teixido (@teixido_c) September 26, 2018
#WCLC18 @SylvesterCancer Great debate on Large Cell NEC, to treat like SCC or NSCLC? No clear data, but NGS may be helpful. RB1 WT do better with NSCLC regimens. Also STK11/KEAP1 mutations are about 20-30%, the benefits of IO’s?Early data suggests benefit though— Dr. Raja Mudad (@DrMudad) September 26, 2018
Here is highlighted the importance of academic programs to limit off label use and assessment of drug efficacy in rare molecular actionnable alterations @MSPneu @IASLC @Institut_cancer @IFCTlung #WCLC18 pic.twitter.com/6Zxt55vwr8— Fabrice Barlesi (@barlesi) September 25, 2018
💨 Radon is a well-known cause of lung cancer.— Dr. Antonio Calles (@Tony_Calles) September 24, 2018
👉 Interestingly, it may be also related to known targetable oncogenic mutations and gene rearrangements, such EGFR, BRAF, HER2, and ROS1.
👏 Highly proud of @LauraMezquitaMD and her work at @GustaveRoussy #LCSM #WCLC2018 @IASLC pic.twitter.com/9cjAP5uPzG
There was also an emphasis on patients.
.@myESMO President Elect @peters_solange speaking at #WCLC2018 Plenary, reminding us that developments in #cancer care are only valuable to extent they're available to pts, which varies remarkably around world. Need to get pts everywhere access to best therapy. #CancerGroundshot pic.twitter.com/29kHvSrFXG— H. Jack West, MD (@JackWestMD) September 24, 2018
Overall, conference-goers thought it was one of the most productive meetings they’ve been to.
#WCLC18 @SylvesterCancer What an exciting time in cancer and especially in #LungCancer This picture exemplifies where we were and where we are going. I find it to be very true, not just for TRK, but for more genes in the tentacles pic.twitter.com/UqsPezs9cB— Dr. Raja Mudad (@DrMudad) September 26, 2018
#WCLC18 @SylvesterCancer I have never been to a meeting where three plenary presentations were practice changing and NEJM publications! #Durvalumab in stage III #NSCLC, #brigatinib in ALK+ first line and #atezolizumab in first line #smallcelllungcancer— Dr. Raja Mudad (@DrMudad) September 25, 2018